Showing 1 - 8 results of 8 for search 'de la Fuente, A', query time: 0.04s Refine Results
  1. 1
    Salvador Allende, por la democracia y el socialismo

    Salvador Allende, por la democracia y el socialismo by José Alberto de la Fuente A

    Published 2011-01-01
    Get full text
    Article
  2. 2
    Muscarinic agonist carbachol depresses excitatory synaptic transmission in the rat basolateral amygdala in vitro.

    Muscarinic agonist carbachol depresses excitatory synaptic transmission in the rat basolateral amygdala in vitro. by Yajeya, J, De La Fuente, A, Criado, J, Bajo, V, Sánchez-Riolobos, A, Heredia, M

    Published 2000
    Journal article
  3. 3
    SITUACIÓN ACTUAL DEL BANCO DE GERMOPLASMA ANDALUZ

    SITUACIÓN ACTUAL DEL BANCO DE GERMOPLASMA ANDALUZ by Vallecillo A., Miró-Arias A., Navas F., De la Fuente A., Camacho M.E., Delgado J.V.

    Published 2011-12-01
    Get full text
    Article
  4. 4
    Birth of a healthy boy after a double factor PGD in a couple carrying a genetic disease and at risk for aneuploidy: case report.

    Birth of a healthy boy after a double factor PGD in a couple carrying a genetic disease and at risk for aneuploidy: case report. by Obradors, A, Fernández, E, Oliver-Bonet, M, Rius, M, de la Fuente, A, Wells, D, Benet, J, Navarro, J

    Published 2008
    Journal article
  5. 5
    Conjugation, labelling and in vitro/in vivo assessment of an anti-VEGF monoclonal antibody labelled with niobium isotopes

    Conjugation, labelling and in vitro/in vivo assessment of an anti-VEGF monoclonal antibody labelled with niobium isotopes by De La Fuente, A, Radchenko, V, Tsotakos, T, Tsoukalas, C, Paravatou-Petsotas, M, Harris, AL, Köster, U, Rösch, F, Bouziotis, P

    Published 2018
    Journal article
  6. 6
    Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]

    Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum] by Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyagüez I, Brockbank J, Iglesias T, Llinares J, Sierra J

    Published 2021-07-01
    Get full text
    Article
  7. 7
    Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain

    Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain by Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyagüez I, Brockbank J, Iglesias T, Llinares J, Sierra J

    Published 2021-04-01
    Get full text
    Article
  8. 8
    AML-262 Pivekimab Sunirine (PVEK, IMGN632) triplet with azacitidine and venetoclax shows broad activity in adverse genetic subsets of relapsed/refractory acute myeloid leukemia and reduced infusion-related reactions

    AML-262 Pivekimab Sunirine (PVEK, IMGN632) triplet with azacitidine and venetoclax shows broad activity in adverse genetic subsets of relapsed/refractory acute myeloid leukemia and... by Daver, N, Montesinos, P, Aribi, A, Martinelli, G, Altman, JK, Wang, ES, Roboz, GJ, Burke, PW, Gaidano, G, Walter, RB, Thomas, X, Jeyakumar, D, DeAngelo, DJ, Erba, HP, Todisco, E, Begna, K, Advani, A, Gastaud, L, de la Fuente, A, Curti, A, Mendez, LM, Vyas, P, Boissel, N, Vey, N, Recher, C, Longval, T, Platzbecker, U, Kapp-Schwörer, S, Schliemann, C, Konopleva, M, Torres, L, Sallman, DA, Marcucci, G, Marconi, G, Kantarjian, H, Sloss, CM, Malcolm, KE, Zweidler-McKay, PA, Sweet, K

    Published 2022
    Journal article

Search Tools: